Cytarabine is the drug of choice for treatment of leukemia. However, many formulations have been prepared, due to certain limitations they could not prove to be effective ones, therefore magnetic microspheres are formulated as they minimize the Reticuloendothelial clearance and target site specificity can be increased. The current study aimed to utilize nanotechnology to develop magnetic micros...

BACKGROUND AND OBJECTIVES Treatment of acute myeloid leukemia (AML) in older patients remains unsatisfactory. The BGMT 95 trial for older patients set out to improve the outcome of these patients by adding a third drug (lomustine) to a 5+7 idarubicin and cytarabine schedule at induction and evaluating intermediate-dose cytarabine as consolidation. DESIGN AND METHODS A multicenter randomized t...

The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase chronic myeloid leukemia (CML). Patients received 2 cycles of intravenous cytarabine (200 mg/m(2) or 1000 mg/m(2) days 1-7) in conjunction with imatinib (200 mg, 400 mg, 600 mg, or 800 mg), according to predefined, successive dose levels. All ...

Potentially fatal lung toxicity occurs in 12-20% of leukemic patients treated with cytarabine especially at intermediate to high doses, usually presenting as noncardiogenic pulmonary edema (NCPE). Anecdotally the association between cytarabine and the onset of bronchiolitis obliterans organizing pneumonia (BOOP) has been reported. We describe here three cases of patients affected by acute myelo...

Fig. 1. Time course for a patient with refractory Burkitt’s leukemia who suffered from fungemia due to Trichosporon dermatis after chemotherapy. Abbreviations: R-hyper CVAD, rituximab+cyclophosphamide hydrate+vincristine sulfate+doxorubicin hydrochloride+dexamethasone; MTX, methotrexate; R-IVAC, rituximab+ifosfamide+etoposide+cytarabine; R-CODOX-M, rituximab+cyclophosphamide hydrate+vincristine...

BACKGROUND AND OBJECTIVE Central nervous system (CNS) involvement in patients diagnosed with acute leukemias (AL) is an uncommon complication with poor prognosis. The indication and the schedules of prophylaxis and treatment of CNS involvement in AL are not homogenous among countries and within the same country. The aim of this prospective longitudinal study was to analyze and report the practi...

Background: Serious cutaneous eruptions caused by cytarabine are never reported in China. Methods: We admitted a 43-year-old man who was diagnosed with acute non-lymphocytic leukemia, and was given several chemotherapy regimens including cytarabine. And when FLAG regimens were given in the patient, the serious pustular eruption appeared. Results: After the treatment, cutaneous eruption was grad...

Developing optimal radiation-free central nervous system prophylaxis is a desirable goal in acute lymphoblastic leukemia, to avoid the long-term toxicity associated with cranial irradiation. In a randomized, phase II trial enrolling 145 adult patients, we compared intrathecal liposomal cytarabine (50 mg: 6/8 injections in B-/T-cell subsets, respectively) with intrathecal triple therapy (methotr...

The prognosis of relapsed acute myeloid leukemia (AML) in elderly patients is dismal, even if the AML exhibits a good prognostic karyotype, such as inv(16)(p13.1q22). We present a 72-year-old female with AML with inv(16)(p13.1q22) who suffered five episodes of relapse with temporary complete remission. Maintenance chemotherapy with oral cytarabine ocfosfate hydrate eventually produced persisten...

Abstract Cytarabine neurotoxicity is well-documented, typically occurring after intrathecal treatment or a cumulative systemic dose of 36 g/m2. Encephalopathy, myelopathy, and acute cerebellar syndrome have all been described, with risk factors including advanced age renal dysfunction. Here, we report case single cycle intravenous cytarabine 3 This 65 year old man history chronic kidney disease...